open access

Vol 76, No 6 (2018)
Short communications
Published online: 2018-06-11
Submitted: 2017-10-26
Accepted: 2018-02-12
Get Citation

miR-1, miR-21, and galectin-3 in hypertensive patients with symptomatic heart failure and left ventricular hypertrophy

Mariusz Tomaniak, Grażyna Sygitowicz, Olga Błaszczyk, Łukasz Kołtowski, Dominika Puchta, Karolina Malesa, Janusz Kochanowski, Dariusz Sitkiewicz, Krzysztof J. Filipiak
DOI: 10.5603/KP.2018.0117
·
Kardiol Pol 2018;76(6):1009-1011.

open access

Vol 76, No 6 (2018)
Short communications
Published online: 2018-06-11
Submitted: 2017-10-26
Accepted: 2018-02-12

Abstract

Not available

Abstract

Not available
Get Citation
Supplementary Files (3)
Supplementary Figure 1
Download
176KB
Supplementary Figure 2
Download
93KB
Supplementary Detailed Results and Figures
Download
102KB
About this article
Title

miR-1, miR-21, and galectin-3 in hypertensive patients with symptomatic heart failure and left ventricular hypertrophy

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Vol 76, No 6 (2018)

Pages

1009-1011

Published online

2018-06-11

DOI

10.5603/KP.2018.0117

Bibliographic record

Kardiol Pol 2018;76(6):1009-1011.

Authors

Mariusz Tomaniak
Grażyna Sygitowicz
Olga Błaszczyk
Łukasz Kołtowski
Dominika Puchta
Karolina Malesa
Janusz Kochanowski
Dariusz Sitkiewicz
Krzysztof J. Filipiak

References (14)
  1. Knöll R, Iaccarino G, Tarone G, et al. Towards a re-definition of 'cardiac hypertrophy' through a rational characterization of left ventricular phenotypes: a position paper of the Working Group 'Myocardial Function' of the ESC. Eur J Heart Fail. 2011; 13(8): 811–819.
  2. Thum T. Noncoding RNAs and myocardial fibrosis. Nat Rev Cardiol. 2014; 11(11): 655–663.
  3. Barwari T, Joshi A, Mayr M. MicroRNAs in Cardiovascular Disease. J Am Coll Cardiol. 2016; 68(23): 2577–2584.
  4. Klimczak D, Pączek L, Jażdżewski K, et al. MicroRNAs: powerful regulators and potential diagnostic tools in cardiovascular disease. Kardiol Pol. 2015; 73(1): 1–6.
  5. Ono K, Kuwabara Y, Han J. MicroRNAs and cardiovascular diseases. FEBS J. 2011; 278(10): 1619–1633.
  6. de Boer RA, Yu L, van Veldhuisen DJ. Galectin-3 in cardiac remodeling and heart failure. Curr Heart Fail Rep. 2010; 7(1): 1–8.
  7. Seto AG, van Rooij E. Circulating microRNAs to identify human heart failure. Eur J Heart Fail. 2012; 14(2): 118–119.
  8. Ali Sheikh MdS, Salma U, Zhang B, et al. Diagnostic, prognostic, and therapeutic value of circulating miRNAs in heart failure patients associated with oxidative stress. Oxid Med Cell Longev. 2016; 2016: 5893064.
  9. Karakikes I, Chaanine AH, Kang S, et al. Therapeutic cardiac-targeted delivery of miR-1 reverses pressure overload-induced cardiac hypertrophy and attenuates pathological remodeling. J Am Heart Assoc. 2013; 2(2): e000078.
  10. Kontaraki JE, Marketou ME, Parthenakis FI, et al. Hypertrophic and antihypertrophic microRNA levels in peripheral blood mononuclear cells and their relationship to left ventricular hypertrophy in patients with essential hypertension. J Am Soc Hypertens. 2015; 9(10): 802–810.
  11. Zhang R, Niu H, Ban T, et al. Elevated plasma microRNA-1 predicts heart failure after acute myocardial infarction. Int J Cardiol. 2013; 166(1): 259–260.
  12. Kuwabara Y, Ono K, Horie T, et al. Increased microRNA-1 and microRNA-133a levels in serum of patients with cardiovascular disease indicate myocardial damage. Circ Cardiovasc Genet. 2011; 4(4): 446–454.
  13. Sharma UC, Pokharel S, van Brakel TJ, et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation. 2004; 110(19): 3121–3128.
  14. Shah RV, Chen-Tournoux AA, Picard MH, et al. Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. Eur J Heart Fail. 2010; 12(8): 826–832.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl